Effects of etanercept in patients with the metabolic syndrome.
about
"Control" laboratory rodents are metabolically morbid: why it mattersIs the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritisRole of cytokines and chemokines in non-alcoholic fatty liver diseaseTargeting inflammation in diabetes: Newer therapeutic optionsAdipokines - removing road blocks to obesity and diabetes therapyInflammation, insulin resistance, and diabetes--Mendelian randomization using CRP haplotypes points upstreamObesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease.Obesity and upper airway control during sleep.Effects of TNF-alpha antagonism on E-selectin in obese subjects with metabolic dysregulationAssociation between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy.Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristicsAnti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease.TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome.Chronic TNF-α neutralization does not improve insulin resistance or endothelial function in "healthy" men with metabolic syndromeFactors related to HIV-associated neurocognitive impairment differ with age.Relation of body composition to body mass index in HIV-infected patients with metabolic abnormalitiesDietary fat intake and relationship to serum lipid levels in HIV-infected patients with metabolic abnormalities in the HAART era.Effects of TNF-alpha neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome.Elimination of the NLRP3-ASC inflammasome protects against chronic obesity-induced pancreatic damageRegulation of LYRM1 gene expression by free fatty acids, adipokines, and rosiglitazone in 3T3-L1 adipocytesTherapeutic approaches to target inflammation in type 2 diabetesInnate and ozone-induced airway hyperresponsiveness in obese mice: role of TNF-α.Central obesity, type 2 diabetes and insulin: exploring a pathway full of thorns.Inflammation as a Link between Obesity and Metabolic Syndrome.Nuclear factor κB-inducing kinase activation as a mechanism of pancreatic β cell failure in obesity.Eicosanoids and renal damage in cardiometabolic syndrome.Molecular targets related to inflammation and insulin resistance and potential interventionsInflammatory mechanisms in the regulation of insulin resistance.A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1Metabolic syndrome in rheumatoid arthritisHyporesponsiveness to the anti-inflammatory action of interleukin-10 in type 2 diabetesAdipokines and the peripheral and neural control of energy balance.Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis.Type 2 diabetes and cardiovascular disease: getting to the fat of the matter.Gene silencing in adipose tissue macrophages regulates whole-body metabolism in obese mice.Plasma levels of inflammatory cytokines in adult Nigerians with the metabolic syndromeObesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review.Paradoxical glucose-sensitizing yet proinflammatory effects of acute ASP administration in mice.Adipokines and hepatic insulin resistanceAdipokines and insulin resistance
P2860
Q24599731-868608E7-6999-445D-BC48-E0D9172C35F1Q26746659-D3453A28-8A0A-48D6-838C-F982D2E64644Q26830328-0DACE309-0479-4DEE-9A8E-BCCF1F548A56Q26852726-015E7C4A-F8E8-4390-9BDF-FB39769EA7D8Q26995825-158AB805-8237-4C88-A54C-C946AE898993Q28473422-5AD33445-80A0-4CB9-8EAD-E48213FCA244Q33580624-BAD49871-E5E3-4447-A25D-AD1F5710467BQ33656629-6F4F21A9-752F-4561-B0B5-789CCAB493CAQ33937394-8B8E4D8A-B908-420F-B807-8B1A5C9220EBQ34153519-5465E212-CB69-41D3-AE2F-7A7CAA73FC0EQ34233328-F9D3CF18-8484-4A05-9E3D-4B04F7F8E7F6Q34444895-A3A22452-BB97-4BFF-8877-6CD5835CCBA8Q34571799-D418A5E6-C792-41A2-B28C-9913601495C9Q34699554-1BC69FB0-09CF-462A-B0F0-E70FE44013C9Q35058626-4C9C1138-4917-4E32-BEAC-0CEEE961AA20Q35369261-2E37A885-D02E-4FD2-B882-8AE34DD89F75Q35370152-877C9EE2-75F0-47E3-89FE-EBD7A6DB0AF1Q35384250-14E82C69-AADD-4E26-BBE6-8231FF90DDBFQ35417136-DB0C3184-F73A-4DE0-B59E-2F5F9E890601Q35495437-1E71BBB1-9243-4766-BD85-7493A717052EQ35581498-D9436B60-612C-4B36-AE65-6BE6E510E22AQ35672041-E6EC863E-2C2D-4150-85C3-49A16DF91F10Q35829203-7EA93814-CBDC-4613-A2BC-31E1CF03CC88Q35864675-BAB542C7-EF2E-4653-9D24-9D873FF7FCD4Q35894344-E1171A02-8D50-4485-B39B-4882E50AD063Q35947602-8AD22083-D5A4-4998-B46C-7055B02C0CA9Q36294297-7CBC79E6-F101-446D-B6F8-CC86491BD790Q36409227-5F61DF3D-E442-4853-913F-DD431D1455B1Q36434758-9A85DA57-3FB7-4E19-804E-873E3FFA3071Q36568868-DA95C598-7348-4EC9-AAC1-C08B1FD80E81Q36588627-78353407-D8D6-417A-A583-50DF62982BCBQ36629302-D62E661A-37C0-4AFD-92C5-DD2BC16CC67FQ36633289-3F89E1EA-CF88-41DD-8524-4EBE2DB74ED7Q36814772-87EFA308-BCBE-454F-A1AA-DC5BE4ED3216Q36855257-9339E650-566E-42EB-AA9C-746F71F97087Q36876733-051FCF46-8655-4399-AE42-52C04C233721Q36879686-EDDDB011-A950-4329-82BC-30C021EDE7FCQ36882808-83ABDB46-8FC7-4AAB-9579-A5662BA36733Q36896425-57C17741-7689-4D79-B8CB-4498A442F8D5Q36972589-3767FC58-E52D-4522-B926-32F6EF64BA2F
P2860
Effects of etanercept in patients with the metabolic syndrome.
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Effects of etanercept in patients with the metabolic syndrome.
@ast
Effects of etanercept in patients with the metabolic syndrome.
@en
type
label
Effects of etanercept in patients with the metabolic syndrome.
@ast
Effects of etanercept in patients with the metabolic syndrome.
@en
prefLabel
Effects of etanercept in patients with the metabolic syndrome.
@ast
Effects of etanercept in patients with the metabolic syndrome.
@en
P2093
P2860
P1476
Effects of etanercept in patients with the metabolic syndrome.
@en
P2093
Bridget Canavan
Jacqueline Berry
L Elizabeth Bernstein
Steven K Grinspoon
Sunnie Kim
P2860
P304
P356
10.1001/ARCHINTE.166.8.902
P407
P577
2006-04-01T00:00:00Z